key: cord-0281504-i3bp5ecn
authors: Ortiz-Martínez, Yeimer; Fajardo-Rivero, Javier E.; Mendoza-Herrera, Tania; Figueroa-Pineda, Claudia; Ruiz-González, Carlos; Saul, Zane; Rodríguez-Morales, Alfonso J.
title: High incidence and mortality of COVID-19 among patients with haematological malignancies: an observational study in santander, Colombia
date: 2022-05-27
journal: nan
DOI: 10.1016/j.nmni.2022.100988
sha: 483be5d7296055edfbe0fa5e93a5c818750afcb5
doc_id: 281504
cord_uid: i3bp5ecn

nan

suggests that patients with HM experience significant morbidity and mortality resulting from 6 COVID-19 infection compared to the general population. 1,2 A recent study on children with HM 7 suggest they are at no greater risk of severe SARS-CoV-2 infection than those with non-HM. 3 8 However, there is a limited number of studies about COVID-19 in patients with HM, particularly 9

in Latin America. Therefore, this study aims to report the real-world incidence and outcomes of 10 COVID-19 in patients with HM compared to the general population in Santander, Colombia. We documented eight COVID-19 cases among 143 HM patients, resulting in an accumulated 25 incidence in 2020 of 5.59% (IC95% 1.48-9.7), which was higher than that of the general 26 population in Santander (3.17%) (ratio 1.76). Four were male; the median age was 65.2 years 27 (range 31-79). Three cases were in patients with chronic lymphocytic leukaemia, two with non-28

Hodgkin's lymphoma, two with multiple myeloma and one with myelodysplastic syndrome. 29 62.5% had relapsed, or refractory disease and only one patient received chemotherapy during 30 hospitalization. The median in-hospital stay was 17.2 days (range 5-31). There were no 31 differences in the COVID-19 incidence between HM subtypes (p=0.2). The COVID-19-related 32 fatality rate was 75% (6/8), considerably higher than the reported in the general population of 

Clinical characteristics and risk factors associated